Dipna Pharmachem

Why is Dipna Pharmachem Ltd falling/rising?

As of 19-Jun, Dipna Pharmachem Ltd's stock price is stable at 7.19, with a recent short-term gain of 2.71%. Despite this, the stock has significant long-term declines, down 57.46% year-to-date and 67.35% over the past year, although increased investor participation may indicate a positive shift.

As of 19-Jun, Dipna Pharmachem Ltd's stock price is currently stable at 7.19, showing no change (0.00%). However, the stock has recently experienced a positive trend, gaining 2.71% over the past week, which indicates a rising momentum in the short term. This performance has outpaced the benchmark Sensex, which rose by 1.69% during the same period. <BR><BR>Despite this recent uptick, the stock has faced significant declines over longer periods, with a year-to-date decrease of 57.46% and a one-year decline of 67.35%. Additionally, the stock is trading below its moving averages across various time frames, suggesting that it may still be under pressure overall. <BR><BR>Investor participation appears to be increasing, as evidenced by a rise in delivery volume, which increased by 4.17% compared to the five-day average. This could indicate growing interest among investors, potentially contributing to the recent gains. <BR><BR>In summary, while Dipna Pharmachem Ltd is currently stable, the recent short-term gains and increased investor participation suggest a positive shift, although the stock continues to face challenges reflected in its longer-term performance metrics.

Which are the latest news on Dipna Pharmachem?

What does Dipna Pharmachem do?

Dipna Pharmachem Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2011 and converted to a public limited company in 2022. It has a market cap of INR 20 Cr, with key metrics including a P/E ratio of 20.00 and a debt-equity ratio of 0.44.

Overview: <BR>Dipna Pharmachem Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Dipna Pharmachem Private Limited was incorporated on July 19, 2011. The company changed its name to "Dipna Pharmachem Private Limited" on March 29, 2012, and later converted from Private Limited to Public Limited, with the name changed to "Dipna Pharmachem Limited" on May 25, 2022. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 20 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.44 <BR>Return on Equity: 2.52% <BR>Price-to-Book: 0.53<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are in the management team of Dipna Pharmachem?

The management team of Dipna Pharmachem includes Keyur Shah (Managing Director), Dipna Shah (Director), Nandish Jani, Chinu Kalal, and Jitendra Parmar (Independent Directors), along with Khushboo Jethaliya and Madhuri Gurwani (Company Secretaries & Compliance Officers).

The management team of Dipna Pharmachem includes the following individuals:<BR><BR>1. Keyur Shah - Managing Director<BR>2. Dipna Shah - Director<BR>3. Nandish Jani - Independent Director<BR>4. Chinu Kalal - Independent Director<BR>5. Khushboo Jethaliya - Company Secretary & Compliance Officer<BR>6. Jitendra Parmar - Independent Director<BR>7. Madhuri Gurwani - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the Dipna Pharmachem?

Dipna Pharmachem's peers include Ishita Drugs, Venmax Drugs, Centuple Global, and others. While Dipna Pharmachem has excellent growth, it shows a significant negative 1-year return of -66.76%, the lowest among its peers.

Peers: The peers of Dipna Pharmachem are Ishita Drugs, Venmax Drugs, Centuple Global, Desh Rakshak, Parmax Pharma, Cian Healthcare, Starsource Multi, Zenith Health, and Colinz Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Below Average management risk is found at Ishita Drugs, Venmax Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, Dipna Pharmachem, Zenith Health, and Colinz Labs, and the rest. Growth is Excellent at Dipna Pharmachem, Good at Centuple Global and Mono Pharmacare, Average at Venmax Drugs, and Below Average at Ishita Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, Zenith Health, and Colinz Labs, and the rest. Capital Structure is Good at Centuple Global and Zenith Health, and Below Average at Ishita Drugs, Venmax Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, Dipna Pharmachem, Starsource Multi, and Colinz Labs, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centuple Global at 105.84%, while the peer with the lowest is Dipna Pharmachem at -66.76%. Dipna Pharmachem's 1-year return is significantly lower than that of its peers. Additionally, the six-month return is negative for Centuple Global, Venmax Drugs, and Dipna Pharmachem.

How has been the historical performance of Dipna Pharmachem?

Dipna Pharmachem has experienced a significant decline in financial performance, with net sales dropping from 727.56 Cr in March 2022 to 124.92 Cr by March 2025, alongside decreasing operating profit and negative cash flow from operations. Despite stable total liabilities, the overall trend indicates ongoing challenges in profitability and sales.

Answer:<BR>The historical performance of Dipna Pharmachem shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Dipna Pharmachem's net sales peaked at 727.56 Cr in March 2022 but have since declined to 124.92 Cr by March 2025. The total operating income followed a similar trend, dropping from 727.56 Cr in March 2022 to 124.93 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline from 22.10 Cr in March 2022 to 3.45 Cr in March 2025, while profit before tax remained relatively stable at 1.42 Cr in March 2025 compared to 1.42 Cr in March 2024. Profit after tax showed a slight decrease from 1.09 Cr in March 2024 to 0.97 Cr in March 2025. The company's total liabilities have remained relatively stable, with a slight decrease from 132.90 Cr in March 2024 to 132.38 Cr in March 2025. Cash flow from operating activities has been negative, with -9.00 Cr in March 2025, indicating ongoing challenges in generating cash from operations. Overall, the financial performance of Dipna Pharmachem reflects a downward trend in sales and profitability over the past few years.

Is Dipna Pharmachem overvalued or undervalued?

As of November 21, 2025, Dipna Pharmachem is considered overvalued due to a high PE ratio of 41.87 and low ROE of 2.52%, despite a strong one-year stock return of 150.22%, especially when compared to peers like Sun Pharma and Cipla.

As of 21 November 2025, Dipna Pharmachem's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its high PE ratio of 41.87, an EV to EBIT ratio of 16.69, and a ROE of only 2.52%. In comparison, peers such as Sun Pharma have a PE of 36.98 and an EV to EBITDA of 24.43, while Cipla, which is rated attractive, has a significantly lower PE of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Given these ratios and the peer comparison, Dipna Pharmachem appears to be overvalued in the current market context. Despite a strong one-year stock return of 150.22%, which outperformed the Sensex's 10.47%, the company's financial metrics suggest that its stock price may not be justified at this level.

When is the next results date for Dipna Pharmachem?

Dipna Pharmachem will announce its results on 26 November 2025.

Dipna Pharmachem will declare its results on 26 November 2025.

How big is Dipna Pharmachem?

As of 23rd July, Dipna Pharmachem Ltd has a market capitalization of 59.00 Cr, categorizing it as a Micro Cap company. Financial data for the latest quarterly performance is unavailable, but as of March 2024, Shareholder's Funds are 37.52 Cr and Total Assets are 132.90 Cr.

As of 23rd July, Dipna Pharmachem Ltd has a market capitalization of 59.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest quarterly performance, including Net Sales and Net Profit for the latest four quarters.<BR><BR>The reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 37.52 Cr and Total Assets valued at 132.90 Cr.

Who are the top shareholders of the Dipna Pharmachem?

The top shareholders of Dipna Pharmachem include promoter Keyur Dipakkumar Shah with 9.97% and public shareholder Teena Kirti Jain with 4.1%. Individual investors hold a significant 71.21% of the shares, with no institutional holdings reported.

The top shareholders of Dipna Pharmachem include Keyur Dipakkumar Shah, who is the promoter with the highest holding at 9.97%. The highest public shareholder is Teena Kirti Jain, holding 4.1%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.21% of the shares. There are no institutional holdings from mutual funds or foreign institutional investors.

What is the technical trend for Dipna Pharmachem?

As of June 2, 2025, Dipna Pharmachem's technical trend is mildly bullish, supported by strong weekly indicators and bullish Bollinger Bands, but tempered by mixed monthly signals and a mildly bearish outlook from Dow Theory.

As of 2 June 2025, the technical trend for Dipna Pharmachem has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The RSI shows no signal on the weekly chart and is bearish on the monthly chart, suggesting weakening momentum. Bollinger Bands are bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, Dow Theory indicates a mildly bearish trend on the weekly chart, which adds caution. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators but tempered by monthly bearish signals.

Has Dipna Pharmachem declared dividend?

No Dividend History Available